Advances in biological regulation
Pharmacological SHIP2 blockade enhances sensitivity to standard and targeted cancer therapies.
Nadia Gillet, Cyril Bodart, Benjamin Beck
Published: 202510.1016/j.jbior.2025.101130
Abstract
Esophageal squamous cell carcinoma (eSCC) is an aggressive malignancy with poor prognosis and limited therapeutic options. The phosphoinositide 3-kinase (PI3K)/AKT pathway is frequently activated in eSCC, but clinical use of PI3K or AKT inhibitors is…
Preview only. Read the full abstract at the source